Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up prior to trading on Monday. The stock had previously closed at $5.51, but opened at $5.83. Valneva shares last traded at $5.7840, with a volume of 1,942 shares trading hands.

Analyst Ratings Changes

A number of research firms have weighed in on VALN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research report on Monday, September 14th. TD Cowen started coverage on shares of Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $9.30.

Valneva Stock Performance

The stock has a market capitalization of $547.97 million, a P/E ratio of -2.74 and a beta of 1.37. The company’s fifty day simple moving average is $6.06 and its two-hundred day simple moving average is $6.76. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The firm had revenue of $39.37 million during the quarter, compared to the consensus estimate of $44.17 million. As a group, equities analysts forecast that Valneva SE Sponsored ADR will post -1.27 EPS for the current year.

About Valneva

Valneva SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.

Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea.